These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31110735)

  • 1. Brentuximab vedotin as monotherapy for unresectable breast implant-associated anaplastic large cell lymphoma.
    Stack A; Levy I
    Clin Case Rep; 2019 May; 7(5):1003-1006. PubMed ID: 31110735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin.
    Stack A; Ali N; Khan N
    J Cell Immunol; 2020 May; 2(3):80-89. PubMed ID: 32914146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.
    Richardson K; Alrifai T; Grant-Szymanski K; Kouris GJ; Venugopal P; Mahon B; Karmali R
    Mol Clin Oncol; 2017 Apr; 6(4):539-542. PubMed ID: 28413663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma.
    Alderuccio JP; Desai A; Yepes MM; Chapman JR; Vega F; Lossos IS
    Clin Case Rep; 2018 Apr; 6(4):634-637. PubMed ID: 29636930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.
    Johnson L; O'Donoghue JM; McLean N; Turton P; Khan AA; Turner SD; Lennard A; Collis N; Butterworth M; Gui G; Bristol J; Hurren J; Smith S; Grover K; Spyrou G; Krupa K; Azmy IA; Young IE; Staiano JJ; Khalil H; MacNeill FA
    Eur J Surg Oncol; 2017 Aug; 43(8):1393-1401. PubMed ID: 28596034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
    Chen X; Soma LA; Fromm JR
    Onco Targets Ther; 2013 Dec; 7():45-56. PubMed ID: 24379682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
    Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G
    Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
    Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
    Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage IV Breast Implant-associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy.
    Thibodeau R; Fan KL; Wehner PB
    Plast Reconstr Surg Glob Open; 2019 Sep; 7(9):e2446. PubMed ID: 31942403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis.
    K Groth A; Graf R
    Aesthetic Plast Surg; 2020 Feb; 44(1):1-12. PubMed ID: 31624894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
    Nizamuddin I; Galvez C; Pro B
    Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.